Sumitomo Chemical Company (4005) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
20 Nov, 2025Executive summary
Achieved a V-shaped recovery in FY2024, with core operating income of JPY 140.5 billion, reversing a loss of JPY 149.0 billion in FY2023, and net income attributable to owners rebounding to JPY 38.6 billion from a significant prior-year loss.
Sales revenue increased 6.5% year-on-year to JPY 2,606.3 billion, with all business segments reporting higher sales.
ROIC improved to 2.2% and ROE to 4.1% from -29.2% year-over-year.
Major impairment losses were reduced to JPY 26.3 billion from JPY 269.4 billion in FY2023, reflecting improved asset utilization.
Financial highlights
Operating income improved to JPY 193.0 billion from a JPY 488.8 billion loss, supported by non-recurring gains and improved segment performance.
Free cash flow was positive at JPY 318.3 billion, a JPY 481.8 billion improvement year-on-year.
Interest-bearing debt decreased by JPY 277.4 billion to JPY 1,286.1 billion, improving the D/E ratio to 1.20.
Overseas sales revenue ratio increased to 69.9% from 68.0% year-on-year.
Total assets decreased by JPY 495.0 billion to JPY 3,439.8 billion, mainly due to share transfers and lower financial assets.
Outlook and guidance
FY2025 sales revenue is forecast at JPY 2,340.0 billion (down 10.2%), with core operating income of JPY 150.0 billion and net income attributable to owners at JPY 40.0 billion.
Dividend per share is projected to rise to JPY 12.00, up from JPY 9.00, with a payout ratio of 49.1%.
Targeting core operating income of JPY 200 billion by FY2027 as per midterm plan.
Underlying profit (excluding business dispositions) targeted at JPY 100.0 billion.
Assumptions include an exchange rate of JPY 145/USD and naphtha price of JPY 68,000/kl.
Latest events from Sumitomo Chemical Company
- Targets JPY 200B core income by 2027 and JPY 350B by 2035, led by Agro and ICT growth.4005
Status Update8 Jul 2026 - Profits soared year-over-year, prompting upward revisions to forecasts and dividends.4005
Q3 20268 Jul 2026 - Profitability rebounded sharply, driven by pharma gains, asset sales, and improved margins.4005
Q2 20268 Jul 2026 - V-shaped profit recovery and portfolio restructuring drive improved FY2024 outlook.4005
Q2 20251 Jul 2026 - Core operating income and net income rose sharply, with FY2026 set for further growth.4005
Q4 202618 May 2026 - Q3 FY2024 delivered a strong profit rebound and segment growth, with guidance maintained.4005
Q3 20259 Jan 2026 - Core operating income rose sharply despite lower sales and FX losses; outlook is positive.4005
Q1 202616 Nov 2025 - Growth strategy leverages tech strengths, reforms, and portfolio upgrades for resilience and efficiency.4005
Status Update25 Sep 2025 - Profitability returned, led by IT-related Chemicals and improved segment results.4005
Q1 202513 Jun 2025